GD2 Specific Chimeric Antigen Receptor (CAR) and Interleukin-15 Expressing Autologous Natural Killer T-cells to Treat Children with Neuroblastoma
Latest Information Update: 18 Nov 2024
At a glance
- Drugs KUR 501 (Primary) ; Cyclophosphamide; Fludarabine
- Indications Neuroblastoma
- Focus Adverse reactions; First in man; Proof of concept
- Acronyms GINAKIT2
Most Recent Events
- 13 Nov 2024 Arms increased from 1 to 2. New arm ' Experimental: GINAKIT cells + Etanercept' added newly.
- 13 Nov 2024 Planned number of patients changed from 36 to 54.
- 27 Jul 2023 Planned End Date changed from 10 Aug 2034 to 10 Aug 2040.